Literature DB >> 28116955

Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Livio Garattini1, Anna Padula1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28116955      PMCID： PMC5349378          DOI： 10.1177/0141076817690395

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  39 in total

Review 1.  Health economists meet the fourth tempter: drug dependency and scientific discourse.

Authors:  S Morgan; M Barer; R Evans
Journal:  Health Econ       Date:  2000-12       Impact factor: 3.046

2.  Pharmacoeconomic analyses: making them transparent, making them credible.

Authors:  D Rennie; H S Luft
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

3.  Conflict of interest and cost-effectiveness analysis.

Authors:  S Krimsky
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

4.  A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics.

Authors:  L Garattini; R Grilli; D Scopelliti; L Mantovani
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 5.  Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

Authors:  Livio Garattini; Francesca Ghislandi; Milene Rangel Da Costa
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

Review 6.  A critical review of the full economic evaluations of pharmacological treatments for colorectal cancer.

Authors:  Livio Garattini; Paola De Compadri; Daniela Koleva; Luca Pasina; Alessandro Nobili
Journal:  J Med Econ       Date:  2008       Impact factor: 2.448

Review 7.  The futility of utility weighting.

Authors:  Robert L Kane
Journal:  J Clin Epidemiol       Date:  2008-12       Impact factor: 6.437

8.  Budget impact analysis in economic evaluation: a proposal for a clearer definition.

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2011-12

9.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

10.  European Medicines Agency: leave the UK but remain the same.

Authors:  Livio Garattini; Alessandro Curto
Journal:  J R Soc Med       Date:  2016-09       Impact factor: 5.344
View more
  6 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

2.  Comment on: 'The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study'.

Authors:  Livio Garattini; Anna Padula
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

3.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

4.  Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.

Authors:  Livio Garattini; Nicholas Freemantle
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

5.  Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis.

Authors:  Mark P Connolly; Saswat Panda; Julien Patris; Bouke P C Hazenberg
Journal:  Orphanet J Rare Dis       Date:  2019-09-18       Impact factor: 4.123

6.  Hospital Pharmacists in Europe: Between Warehouse and Prescription Pad?

Authors:  Livio Garattini; Anna Padula
Journal:  Pharmacoecon Open       Date:  2018-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.